A Feasibility Study of Gemcitabin and Bevacizumab in patients with Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Trial ID # UMIN000016619
Phase II
Drug Class Angiogenesis Inhibitors: VEGF
Drug Name Bevacizumab
Alternate Drug Names immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial Bevacizumab, Gemcitabine
Eligible Participant

Platinum resistant ovarian cancer with 1-3 prior platinum regimens, no prior bevacizumab

Patients Enrolled

19 patients, median 1 prior therapy (1-2); 12 Pt-S, 7 Pt-Rf

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, PFS, OS, evaluated per RECIST


ORR: 42% (3CR, 5PR, n=19)
DCR: 84% (3CR, 5PR, 8SD, n=19)
PFS: 5.1 months
OS: 21.3 months

Clinically Significant Adverse Events

Serious AE: 1 patient w/ pulmonary embolism
Grade 3-4 AE: decreased neutrophils (47%), proteinuria (21%), hypertension (16%), anemia (11%), nausea (11%)


The combination chemotherapy with gemcitabine and bevacizumab is feasible, effective and safe


Nagao S et al. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Ovarian Res (2020) 13(1):14

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.